Immunotherapy shows long-term promise in aggressive lymphoma
A leading-edge immunotherapy may extend survival for patients with one of the most aggressive forms of blood cancer, according to newly published five-year results from a major clinical trial in the Blood Journal. The clinical trial evaluated lisocabtagene maraleucel (liso-cel),